New combo therapy aims to boost breast cancer treatment before surgery

NCT ID NCT07506876

Recruiting now Disease control Sponsor: Legacy Health System Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combination leads to higher rates of complete tumor disappearance at the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER - INFILTRATING DUCTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma hormone receptor-positive breast cancer invasive ductal breast carcinoma triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER - INFILTRATING DUCTAL CARCINOMA HER 2 POSITIVE BREAST CANCER

Contacts and locations

Locations

Legacy Good Samaritan Medical Center
RECRUITING

Portland, Oregon, 97210, United States
Legacy Meridian Park Medical Center
RECRUITING

Tualatin, Oregon, 97062, United States
Legacy Mount Hood Medical Center
RECRUITING

Gresham, Oregon, 97030, United States
Legacy Salmon Creek Medical Center
RECRUITING

Vancouver, Washington, 98686, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.